Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks That Should Help You Retire Rich

By Keith Speights – Feb 23, 2020 at 9:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All three stand to benefit from major long-term growth trends.

No one wants to spend his or her retirement years scrimping just to get by. The best way to avoid such a fate is to begin socking away money for retirement now and investing that money in assets that deliver excellent long-term returns.

You can cross bonds, CDs, and money market accounts off the list right out of the gate. While these can be relatively safe places to park some money, they won't give you the level of gains that you'll need to amass a comfortable retirement nest egg.

If you want to really be set for retirement, the best place to invest your money is in solid growth stocks. Three growth stocks that should help you retire rich are Guardant Health (GH 0.20%), MongoDB (MDB 1.92%), and The Trade Desk (TTD -1.73%).

Smiling man holding his hands up as money rains down from the sky

Image source: Getty Images.

1. Guardant Health

Guardant Health's shares skyrocketed nearly 108% higher in 2019. This tremendous gain should be just the beginning for the diagnostics company's growth story.

Two products have fueled Guardant Health's meteoric rise -- Guardant360 and GuardantOmni. Both are liquid biopsies that detect DNA fragments in the blood that have broken off from tumor cells. Guardant360 is used to match cancer patients with the most effective treatment option. Biopharmaceutical companies use GuardantOmni to screen prospective patients for clinical trials evaluating cancer drugs.

Look for Guardant360 and GuardantOmni to accelerate their already-strong sales momentum in 2020 and beyond. Guardant Health thinks that Guardant360 by itself could eventually generate annual sales of around $6 billion.

But the company has an even greater opportunity with its Lunar liquid biopsy assays that are currently available for research use only. Lunar-1 is designed to be used for recurrence monitoring of cancer in patients while Lunar-2 targets early cancer detection. The two products together could address an annual market of more than $45 billion. With Guardant Health's market cap at close to $8 billion right now, this stock should have tremendous upside potential.

2. MongoDB

MongoDB's name tells the company's story in a nutshell. Mongo is short for "humongous." DB, of course, stands for database. And MongoDB's powerful database platform gives the company a humongous growth opportunity.

Sure, databases have been around for decades. The problem, though, is that these databases weren't designed for today's world of unstructured data. They were also created to run in on-premises data centers, while in the 2020s everything is moving to the cloud. MongoDB's open-source database platform, on the other hand, was built from the ground up to handle any kind of data, including unstructured data, and to be run anywhere, including the cloud.

It's not surprising that MongoDB's revenue soared 52% year over year in the third quarter of 2019. Although the company still isn't profitable, it's just a matter of time before the profits begin pouring in.

MongoDB's future looks very bright. The already-huge global database market is growing. Mongo's market share is increasing faster than its major rivals. Its Atlas cloud-based fully managed database management product continues to enjoy exceptionally strong momentum. MongoDB stock jumped 57% in 2019 and has already vaulted over 35% higher so far in 2020. More big gains should be on the way over the long run.

3. The Trade Desk

The Trade Desk was the biggest winner among these great growth stocks last year, with its shares zooming nearly 124% higher. There are two trends powering the company's rise: (1) the shift to digital advertising, and (2) the shift to programmatic ad buying. Simply put, The Trade Desk's platform is paving the way for the future of advertising. 

You can just look around throughout the day to see how advertising is going digital. Websites, social media, and many streaming TV services incorporate ads that target specific audiences. And there are way too many advertising opportunities now for the back-and-forth negotiations used in the past to buy and sell ads to be effective. Programmatic advertising addresses this by using software to bid on and buy ads in ways that optimize advertising budgets.

At this point, only a small fraction of the buying and selling in the total global advertising market is done programmatically. But that's going to change. It seems like a safe bet that in the future practically all advertising will be digital and be transacted programmatically.

The Trade Desk is already very profitable. Its revenue continues to grow rapidly. The company should benefit in the near term from the explosive growth of connected TV and its efforts to move into more international markets and stands to prosper over the long term from the shift to digital and programmatic advertising. With a market cap of around $14 billion, The Trade Desk should have plenty of room to run and help you retire rich.

Keith Speights owns shares of Guardant Health, MongoDB, and The Trade Desk. The Motley Fool owns shares of and recommends Guardant Health, MongoDB, and The Trade Desk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Trade Desk Stock Quote
The Trade Desk
$59.75 (-1.73%) $-1.05
MongoDB Stock Quote
$198.56 (1.92%) $3.74
Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$53.83 (0.20%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.